Novel Approaches for Vaccine Development

Overview

Journal Cell

Publisher Cell Press

Specialty Cell Biology

Date 2021 Mar 19

PMID 33740454

Citations 122

Authors

Makda S Gebre

Luis A Brito

Lisa H Tostanoski

Darin K Edwards

Andrea Carfi

Dan H Barouch

Affiliations

Soon will be listed here.

Abstract

Vaccines are critical tools for maintaining global health. Traditional vaccine technologies have been used across a wide range of bacterial and viral pathogens, yet there are a number of examples where they have not been successful, such as for persistent infections, rapidly evolving pathogens with high sequence variability, complex viral antigens, and emerging pathogens. Novel technologies such as nucleic acid and viral vector vaccines offer the potential to revolutionize vaccine development as they are well-suited to address existing technology limitations. In this review, we discuss the current state of RNA vaccines, recombinant adenovirus vector-based vaccines, and advances from biomaterials and engineering that address these important public health challenges.

Citing Articles

Antivirotics based on defective interfering particles: emerging concepts and challenges.

Maryanchik S, Borovikova S, Ivanova A, Trofimov V, Bagrova O, Frolova A Front Cell Infect Microbiol. 2025; 15:1436026.

PMID: 40066067 PMC: 11891348. DOI: 10.3389/fcimb.2025.1436026.

Current status of recombinant duck enteritis virus vector vaccine research.

Jia W, Wang A, Wu Z, Lei X, Cheng Y, Zhu S Front Vet Sci. 2025; 12:1453150.

PMID: 39974164 PMC: 11836020. DOI: 10.3389/fvets.2025.1453150.

Recent advances in the biosynthesis of polysaccharide-based antimicrobial glycoconjugate vaccines.

Wang Y, Liu H, Wang B, Gheyret G, Qin J, Wang H Front Microbiol. 2025; 15:1457908.

PMID: 39943962 PMC: 11813929. DOI: 10.3389/fmicb.2024.1457908.

Bioinformatics and immunoinformatics approaches in the design of a multi-epitope vaccine targeting CTLA-4 for melanoma treatment.

Noor F, Shahid S, Fatima M, Haider S, Al Shehri Z, Alshehri F Mol Divers. 2025; .

PMID: 39873886 DOI: 10.1007/s11030-025-11108-7.

Expanding the Potential of Circular RNA (CircRNA) Vaccines: A Promising Therapeutic Approach.

Bu T, Yang Z, Zhao J, Gao Y, Li F, Yang R Int J Mol Sci. 2025; 26(1.

PMID: 39796233 PMC: 11722184. DOI: 10.3390/ijms26010379.

References

Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Narayanannair Jayaprakash K . Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010; 18(7):1357-64. PMC: 2911264. DOI: 10.1038/mt.2010.85. View

John S, Yuzhakov O, Woods A, Deterling J, Hassett K, Shaw C . Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine. 2018; 36(12):1689-1699. DOI: 10.1016/j.vaccine.2018.01.029. View

Zaiss A, Machado H, Herschman H . The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem. 2009; 108(4):778-90. PMC: 2822460. DOI: 10.1002/jcb.22328. View

Yenkoidiok-Douti L, Jewell C . Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases. ACS Biomater Sci Eng. 2020; 6(2):759-778. PMC: 7725244. DOI: 10.1021/acsbiomaterials.9b01255. View

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

Fries C, Curvino E, Chen J, Permar S, Fouda G, Collier J . Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health. Nat Nanotechnol. 2020; 16(4):1-14. DOI: 10.1038/s41565-020-0739-9. View

Barouch D, Tomaka F, Wegmann F, Stieh D, Alter G, Robb M . Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018; 392(10143):232-243. PMC: 6192527. DOI: 10.1016/S0140-6736(18)31364-3. View

Rosenfeld M, Yoshimura K, Trapnell B, Yoneyama K, Rosenthal E, Dalemans W . In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell. 1992; 68(1):143-55. DOI: 10.1016/0092-8674(92)90213-v. View

Abbink P, Lemckert A, Ewald B, Lynch D, Denholtz M, Smits S . Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007; 81(9):4654-63. PMC: 1900173. DOI: 10.1128/JVI.02696-06. View

10.

Geall A, Verma A, Otten G, Shaw C, Hekele A, Banerjee K . Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A. 2012; 109(36):14604-9. PMC: 3437863. DOI: 10.1073/pnas.1209367109. View

11.

van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham J, Port J . ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020; 586(7830):578-582. PMC: 8436420. DOI: 10.1038/s41586-020-2608-y. View

12.

Corbett K, Flynn B, Foulds K, Francica J, Boyoglu-Barnum S, Werner A . Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020; 383(16):1544-1555. PMC: 7449230. DOI: 10.1056/NEJMoa2024671. View

13.

Hayton E, Rose A, Ibrahimsa U, Del Sorbo M, Capone S, Crook A . Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PLoS One. 2014; 9(7):e101591. PMC: 4090156. DOI: 10.1371/journal.pone.0101591. View

14.

Geisbert T, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D . Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol. 2011; 85(9):4222-33. PMC: 3126236. DOI: 10.1128/JVI.02407-10. View

15.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

16.

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

17.

Baden L, Stieh D, Sarnecki M, Walsh S, Tomaras G, Kublin J . Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. Lancet HIV. 2020; 7(10):e688-e698. PMC: 7529856. DOI: 10.1016/S2352-3018(20)30229-0. View

18.

Pandey A, Galvani A . The global burden of HIV and prospects for control. Lancet HIV. 2019; 6(12):e809-e811. DOI: 10.1016/S2352-3018(19)30230-9. View

19.

Conrad S, Liu J . Poxviruses as Gene Therapy Vectors: Generating Poxviral Vectors Expressing Therapeutic Transgenes. Methods Mol Biol. 2019; 1937:189-209. PMC: 6855597. DOI: 10.1007/978-1-4939-9065-8_11. View

20.

Hassett K, Benenato K, Jacquinet E, Lee A, Woods A, Yuzhakov O . Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. Mol Ther Nucleic Acids. 2019; 15:1-11. PMC: 6383180. DOI: 10.1016/j.omtn.2019.01.013. View